MicroVention Announces FDA Premarket Approval of a New Flow Diverter for the Treatment of Brain Aneurysms
TERUMO CORP UNSP/ADR (TRUMY)
NASDAQ:AMEX Investor Relations:
terumo.com/investor/library/index.html
Company Research
Source: PR Newswire
ALISO VIEJO, Calif., Jan. 9, 2020 /PRNewswire/ -- MicroVention, Inc., a U.S. based subsidiary of Terumo and a global neurovascular company announced the FDA Premarket Approval (PMA) for the FRED® (Flow Re-Direction Endoluminal Device) device for the treatment of brain aneurysms. The FRED® device is the first flow diverter in the U.S. to use a self-expanding braided nitinol mesh to help re-direct blood flow and promote aneurysm occlusion. The unique interwoven nitinol design of the FRED® device allows for smooth delivery to the target aneurysm, as well as reliable opening and vessel wall apposition, resulting in high treatment durability."The FRED® device represents a step forward in flow diversion technology with the inclusion of the lowest profile delivery platform in the U.S. This advancement will allow physicians to more easily access and treat wide-necked or fusiform aneurysms," said Dr. Cameron McDougall, Director of Endovascular Neurosurgery and Professor of Neurosurgery at The
Show less
Read more
Impact Snapshot
Event Time:
TRUMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TRUMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TRUMY alerts
High impacting TERUMO CORP UNSP/ADR news events
Weekly update
A roundup of the hottest topics
TRUMY
News
- With a CAGR of 7.6% from 2025 to 2034, the lancets market is expected to reach USD 12.23 billion by 2034 | PMR [Yahoo! Finance]Yahoo! Finance
- Terumo Health Outcomes and Medis strike cardiovascular care partnership [Yahoo! Finance]Yahoo! Finance
- Terumo Health Outcomes and Medis Medical Imaging Announce Strategic Partnership to Enhance Cardiovascular Care [Yahoo! Finance]Yahoo! Finance
- Terumo Health Outcomes and Medis Medical Imaging Announce Strategic Partnership to Enhance Cardiovascular CarePR Newswire
- Terumo Interventional Systems Announces Launch of Its R2P NaviCross Peripheral Support Catheter [Yahoo! Finance]Yahoo! Finance